During the past decade, Hendersonville Hematology and Oncology at Pardee conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 36 clinical trials were completed, i.e. on average, 109.1% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 32 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hendersonville Hematology and Oncology at Pardee" #1 sponsor was "National Cancer Institute (NCI)" with 25 trials, followed by "SWOG Cancer Research Network" with 21 trials sponsored, "Alliance for Clinical Trials in Oncology" with 3 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 3 trials sponsored and "Eastern Cooperative Oncology Group" with 3 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hendersonville Hematology and Oncology at Pardee" #1 collaborator was "National Cancer Institute (NCI)" with 29 trials as a collaborator, "Canadian Cancer Trials Group" with 3 trials as a collaborator, "NRG Oncology" with 2 trials as a collaborator, "Academic GI Cancer Consortium (AGICC)" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Hendersonville Hematology and Oncology at Pardee" are "Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (7 trials), "Recurrent Breast Carcinoma" (5 trials), "Breast Cancer" (4 trials) and "Stage IV Cutaneous Melanoma AJCC v6 and v7" (4 trials). Many other conditions were trialed in "Hendersonville Hematology and Oncology at Pardee" in a lesser frequency.

Most popular intervention types in "Hendersonville Hematology and Oncology at Pardee" are "Drug" (47 trials), "Other" (39 trials), "Biological" (19 trials), "Procedure" (5 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (29 trials), "Quality-of-Life Assessment" (9 trials), "Placebo Administration" (8 trials), "Ipilimumab" (7 trials) and "Nivolumab" (7 trials). Other intervention names were less common.

The vast majority of trials in "Hendersonville Hematology and Oncology at Pardee" are 47 trials for "All" genders, 8 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hendersonville Hematology and Oncology at Pardee". undefined are not yet recruiting, 5 are recruiting, 30 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Hendersonville Hematology and Oncology at Pardee, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Hendersonville Hematology and Oncology at Pardee, 4 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 28 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".